drugset / Trial / NCT01987284

SER100 in Isolated Systolic Hypertension

NCT01987284 ↗

RandomizedCrossoverQuadruple-blindTreatment

Summary

Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity. In previous clinical studies carried out in individuals with normal blood pressure at baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the effect on systolic blood pressure in hypertensive patients will be larger or equal to the fall seen in normotensive patients.

Timeline

Start
2013-10
Primary completion
2014-07
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SER100 Protein / enzyme biologic 10 mg Subcutaneous

Indications

No indication recorded.